INNO-220 is a molecular glue degrader targeting CK1alpha, exhibiting oral activity and CRBN dependency, capable of inducing cell cycle arrest at G0/G1 phase and apoptosis. INNO-220 disrupts the assembly and function of the CARD11/BCL10/MALT1 complex, inhibits the NF-kappaB signaling pathway, and activates the p53 pathway, making it suitable for lymphoma research.